MabPharm patents CMAB020 in China, out-licenses to Sorrento for US, EU



Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (02181.HK) filed a patent for its bifunctional antibody fusion protein CMAB020 at the China National Intellectual Property Administration (CNIPA). The drug is designed to prevent and treat SARS-CoV / Severe Acute Respiratory Syndrome (SARS), and SARS-CoV-2 / COVID-19. On the same day, US firm Sorrento Therapeutics Inc., (NSDQ:SRNE) entered a licensing deal with MabPharm’s wholly owned subsidiary Mabpharm HK Ltd, taking exclusive development and commercialization rights to CMAB020 in North America and the European Union (EU).

CMAB020 is an in-house developed fusion protein with two functions – coronavirus S protein-targeting monoclonal antibody (mAb) with high affinity, and truncated angiotensin-converting enzyme 2 (ACE2) protein – both of which can exert a synergistic effect and provide passive immunity for the body to prevent viral infection. CMAB020 is designed to block the life cycle of the virus, and can alleviate severe acute respiratory distress syndrome (SARDS) caused by COVID-19 and protect organs. ACE2 retains angiotensin II-converting enzyme activity, which can reduce vasoconstriction in the infected lung and increase blood perfusion, and thus is potentially effective in severe COVID-19 patients. CMAB020 also inhibits the binding of CD147 to receptors, thus reducing lung inflammation and cytokine storms.

Reference:

Related news
Henan Normal University (HNU) revealed that a reverse transcriptase HIV therapy named azvudine (also known as FNC and RO-0622) produced strong therapeutic benefit for patients suffering from the novel coronavirus-linked pneumonia COVID-19.
China-based Lee’s Pharmaceutical Holdings Ltd (950.HK) announced ethics committee approval for a combination therapy of aliskiren with nifedipine.
Brazil’s National Health Surveillance Agency (ANVISA) last week published a notice recommending companies whose products contain chemically synthesized molecules to review their active pharmaceutical ingredients (APIs) processing methods, while requesting manufacturers to ensure the absence of nitrosamine impurities along the synthesis chain and to carry out tests when a contamination risk is detected.
UK based major AstraZeneca (AZ; NYSE.AZN) trumpeted market approval in China for Lokelma (sodium zirconium cyclosilicate) as a treatment for adult patients with hyperkalemia (elevated levels of potassium in the blood).
  • 1578362332971
  • China
  • Drug
The Center for Drug Evaluation (CDE) website reveals that China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (002294.SZ)’s SAL-086-A/F (allisartan+sacubitril) has gained tacit clinical trial approval to begin assessment as a treatment for primary hypertension and chronic heart failure in adults, and to reduce risk of cardiovascular death and hospitalization due to heart failure.
Recent news
The National Medical Products Administration (NMPA) last week revealed that Celgene’s Abraxane (paclitaxel, albumin bound) would lose its import clearance after agency inspectors uncovered manufacturing issues at the Fresenius Kabi plant responsible for manufacturing the drug. The news impacts Chinese biotech BeiGene Inc., which generated around USD 100 million with Abraxane in China as the drug's marketing agent under license from Celgene.
  • 1585666816337
  • China
Pfizer subsidiary Wyeth this week obtained a marketing approval from Brazil's National Health Surveillance Agency (ANVISA) for its iron replacement therapy Monofer (ferric derisomaltose), as GBI analysis shows.
Hugo Sigman, founder of of Argentina-based group Insud Pharma, last week commented on Argentina’s biopharmaceutical industry as the COVID-19 pandemic puts the health sector to test.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) released its Q4 2019 financial report.
According to GBI analysis, Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS) has published recent market approvals for Swiss major Novartis subsidiary Sandoz’s Arasamila (rituximab), Japan-based Daiichi Sankyo’s factor Xa (FXa) inhibitor Lixiana (edoxaban), and compatriot Takeda branch Baxalta’s antihemophilic Adynovate (rurioctocog alfa pegol).
GoBroad Healthcare Group broke ground on construction of a research hospital in Beijing’s Future Science Park this week.
Analytics Snapshot


Analytics Snapshot